Well they have this plan up to 150,000,000 shares.The Plan...

Well they have this plan up to 150,000,000 shares.

The Plan permits the issue of up to 150,000,000 shares in the Company to employees and other persons during the period of 3 years following the
approval date. The LTI will be delivered in the form of performance rights to
acquire shares (‘Rights’), with vesting subject to performance hurdles over a 4
year period, with the first tranche not being eligible to vest before the date
that is 12 months following FDA approval of Sofpironium Bromide (SB) as
follows

• Tranche 1 – 12 months following FDA approval, provided that the FDA
approved label for SB includes efficacy and safety data that supports
promotion in the US market (9,333,334 Rights);
• Tranche 2 – the earlier of the date that is 12 months after the vesting
date of Tranche 1 or 30 Deember 2025, provided that SB has been
launched commercially in the US and the Company has also
established a distribution network that is effectively providing
reimbursed prescriptions to patients (9,333,33 Rights);
• Tranche 3 - 12 months after the vesting date of Tranche 2, provided
that the Company has deployed its digital telehealth platform for the
diagnosis of patients with hyperhidrosis and the Company is also
generating revenue as a direct result from the utilization of the
telehealth platform (9,333,333 Rights);
Tranche 4 – achieving US$45 million of revenue from sales of SB in a
financial year (7,000,000 Rights);
• Tranche 5 – achieving US$100 million of revenue from sales of SB in a
financial year (7,000,000 Rights);
• Tranche 6 – achieving US$150 million of revenue from sales of SB in a
financial year (7,000,000 Rights); and
• Tranche 7 – achieving US$250 million of revenue from sales of
products in a financial year (7,000,000 Rights).

The eligibility of Dr McKibbon to receive each Tranche of Rights is also
dependent upon having had continuous employment with the Company up to
and including the date that the relevant vesting conditions are satisfied.